INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 411m ago
HOUSE PTR11m ago
SEC 13F11m ago
ROBINHOOD CHAIN10m ago
Corporate insider
LY

Li Yishan

Director, Executive Chairman, 10% OwnerCIK 0001772233

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 0
Max Insider Score13
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
1.60M sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    BlossomHill Therapeutics, Inc.Director, Executive Chairman, 10% Owner · Aug 10, 2026
13
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C
—
113.4K sh
Aug 10, 2026
Aug 10, 2026
traded Aug 10, 2026
+0d
SEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Grant or award
A—
112.7K sh
Aug 6, 2026Aug 10, 2026
traded Aug 6, 2026
+4dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
1.60M sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
113.4K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
124.8K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence

9
LY
Li YishanDirector, Executive Chairman, 10% Owner
BLSMBlossomHill Therapeutics, Inc.
Derivative conversion
C—
124.8K sh
Aug 10, 2026Aug 10, 2026
traded Aug 10, 2026
+0dSEC FORM 4

Evidence